Rep. Kevin Hern Sells Boston Scientific Corporation (NYSE:BSX) Stock

Representative Kevin Hern (R-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on November 16th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on October 28th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 10/28/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 10/28/2025.
• Sold $1,001 – $15,000 in shares of O’Reilly Automotive (NASDAQ:ORLY) on 10/28/2025.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 10/28/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 10/28/2025.
• Sold $100,001 – $250,000 in shares of Accenture (NYSE:ACN) on 10/27/2025.
• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 10/23/2025.
• Sold $100,001 – $250,000 in shares of McDonald’s (NYSE:MCD) on 10/23/2025.
• Sold $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 10/6/2025.
• Sold $15,001 – $50,000 in shares of Masimo (NASDAQ:MASI) on 9/26/2025.

Boston Scientific Stock Down 2.5%

BSX opened at $99.23 on Wednesday. The firm has a market cap of $147.10 billion, a P/E ratio of 53.06, a PEG ratio of 2.02 and a beta of 0.58. The business’s fifty day simple moving average is $99.41 and its 200 day simple moving average is $102.51. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. Truist Financial raised their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Wells Fargo & Company lifted their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. UBS Group raised their price target on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average target price of $123.77.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the period. State Street Corp lifted its holdings in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC boosted its position in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank acquired a new stake in Boston Scientific in the 2nd quarter valued at $2,089,937,000. Finally, Invesco Ltd. increased its holdings in Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after purchasing an additional 111,826 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.